SpyGlass Pharma Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
SpyGlass Pharma Inc.
Former names
SpyGlassPharma, Inc. SpyGlass Ophthalmics, Inc.
Ownership
Public
Status
Active
SIC code
3841 — Surgical & Medical Instruments & Apparatus
Jurisdiction of incorporation
Delaware
Headquarters city
Irvine
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
SGP
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001778922
EIN
83-3044245

Board of directors

Follow this board

Chief executives

Patrick H. Mooney · Chief Executive Officer
Since February 2026

Board connections

9 of this board's directors also sit on 34 other boards.

Network of SpyGlass Pharma Inc.'s board connections Nkarta Inc. Nkarta Inc. Black Diamond Therapeutics Inc. Black Diamond Therapeu... Jade Biosciences Inc. Jade Biosciences Inc. LENZ Therapeutics Inc. LENZ Therapeutics Inc. PepGen Inc. PepGen Inc. Tyra Biosciences Inc. Tyra Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Bicara Therapeutics Inc. Bicara Therapeutics In... CVRx Inc. CVRx Inc. Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Ali Behbahani Ali Behbahani Habib J. Dable Habib J. Dable Kirk G. Nielsen Kirk G. Nielsen Michael Dybbs Michael Dybbs Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Zachary Scheiner Zachary Scheiner SpyGlass Pharma Inc.
Shared director Other board Same sector +18 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$221,480,000
17 purchases by 15 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Feb 9, 2026 RA Capital Healthcare Fund LP Director, 10% owner Derivative conversion +2,524,473 — —
Feb 9, 2026 Ali Behbahani Director, 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Florence Anthony A. Jr. 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 BASKETT FOREST 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 NEA 17 GP, LLC 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Yang Rick 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Makhzoumi Mohamad 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Scott D. Sandell 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Edward T. Mathers 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Carmen Chang 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Walker Paul Edward 10% owner Derivative conversion +1,619,240 — —
Feb 9, 2026 Geoffrey B. Pardo Director Derivative conversion +1,875,013 — —
Feb 9, 2026 Bilal Arshad Khan Director Open-market purchase +20,000 $16.00 $320,000
Feb 9, 2026 Kirk G. Nielsen Director Derivative conversion +1,690,230 — —
Feb 9, 2026 Vensana Capital I GP, LLC 10% owner Derivative conversion +1,690,230 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.